Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 10/20 | 0.44 |
| ▸ | TP53 | P04637 | 8/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8281358 | 0.83 | CYP2C9 (0.44) | CYP1A2CYP19A1CYP2C9CYP2C19MAPT | |
| SCHEMBL12021736 | 0.83 | CYP1A2 (0.44) | CYP1A2CYP19A1CYP2C9CYP2C19MAPT | |
| SCHEMBL8226298 | 0.81 | CYP1A2 (0.43) | CYP1A2CYP19A1CYP2C9CYP2C19MAPT | |
| SCHEMBL2272084 | 0.79 | CYP1A2 (0.54) | CYP1A2CYP19A1CYP2C9CYP2C19MAPT | |
| SCHEMBL7832181 | 0.79 | MAPT (0.47) | CYP1A2CYP19A1CYP2C9CYP2C19MAPT | |
| SCHEMBL30624472 | 0.79 | MAPT (0.47) | CYP1A2CYP19A1CYP2C9CYP2C19MAPT | |
| SCHEMBL7904001 | 0.76 | MAPT (0.64) | CYP1A2CYP19A1CYP2C9CYP2C19MAPT | |
| SCHEMBL13514282 | 0.76 | CYP1A2 (0.54) | CYP1A2CYP19A1CYP2C9CYP2C19MAPT | |
| SCHEMBL24799555 | 0.75 | RPS6KB1 (0.52) | CYP1A2CYP19A1CYP2C9CYP2C19MAPT | |
| SCHEMBL8262139 | 0.75 | MEN1 (0.49) | CYP1A2CYP19A1CYP2C9CYP2C19MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7465740-B2 | 2-heteroaryl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists | SCHERING CORPORATION (US) | 2008-12-16 | — | — | US | disclosed |
| US-20070066620-A1 | 2-Heteroaryl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists | MERCK SHARP & DOHME LLC | 2007-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066620-A1 | 2-Heteroaryl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists | ADORA2A, ADORA3, ADORA1 | CYP1A2 1211/4885CYP19A1 4475/4885CYP2C9 2677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.